1. Volume 15, Issue 2, Pages 255-260 (March 2012)
Cost-Effectiveness of Adjuvant FOLFOX Therapy for Stage III Colon Cancer in Japan Based on the MOSAIC Trial 
Takeru Shiroiwa, Toshihiro Takeuchi, Takashi Fukuda, Kojiro Shimozuma, Yasuo Ohashi 
Value in Health 
Volume 15, Issue 2, Pages (March 2012)
DOI: /j.jval
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Estimated cumulative incidence function curves: (A) FOLFOX and (B) 5-fluorouracil/leucovorin (FU/LV). DFS, disease-free survival.
Value in Health  , DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Estimated overall survival curves. FU/LV, 5-fluorouracil/leucovorin.
Value in Health  , DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Distribution of incremental effectiveness (IE) and incremental cost (IC). JPY, Japanese yen.
Value in Health  , DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4 Acceptability curve. JPY, Japanese yen.
Value in Health  , DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions